Aclaris Therapeutics (NASDAQ:ACRS) is set to post its quarterly earnings results after the market closes on Wednesday, May 8th. Analysts expect Aclaris Therapeutics to post earnings of ($0.77) per share for the quarter.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings results on Monday, March 18th. The biotechnology company reported ($0.99) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.96) by ($0.03). The firm had revenue of $3.67 million for the quarter, compared to analyst estimates of $4.40 million. Aclaris Therapeutics had a negative net margin of 1,315.41% and a negative return on equity of 72.13%. On average, analysts expect Aclaris Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Shares of Aclaris Therapeutics stock opened at $6.60 on Tuesday. The stock has a market cap of $261.65 million, a PE ratio of -1.64 and a beta of 1.24. The company has a debt-to-equity ratio of 0.14, a current ratio of 6.57 and a quick ratio of 6.54. Aclaris Therapeutics has a 52-week low of $5.04 and a 52-week high of $21.97.

ACRS has been the subject of several research reports. Cantor Fitzgerald reiterated a “buy” rating and set a $50.00 price target on shares of Aclaris Therapeutics in a report on Friday, March 15th. BidaskClub lowered Aclaris Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, January 19th. Leerink Swann initiated coverage on Aclaris Therapeutics in a report on Monday. They set an “outperform” rating for the company. Finally, Zacks Investment Research lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, March 13th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $26.19.

A hedge fund recently raised its stake in Aclaris Therapeutics stock. Geode Capital Management LLC grew its position in shares of Aclaris Therapeutics Inc (NASDAQ:ACRS) by 38.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 380,007 shares of the biotechnology company’s stock after buying an additional 105,361 shares during the quarter. Geode Capital Management LLC owned approximately 0.93% of Aclaris Therapeutics worth $2,808,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 94.50% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at

About Aclaris Therapeutics

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.

Further Reading: What are municipal bonds?

Earnings History for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with's FREE daily email newsletter.